

Segment	Major Product	Existing	Expansion	Total	Dec Qtr	Mar Qtr	Growth %	Company Comments
		MT/Annum			Amt (In			
Anti-hypertensive	Atenolol	300	120	420	1,418.22	1,153.85	-19%	Received US FDA approval for its Anti-hypertensive Drug Atenolol Plans to capture major share of the US Atenolol market in the next two years.
Macrolides	Azithromycin	30	60	90	3,084.68	3,428.68	11%	During the pandemic, COVID-19, we are manufacturing Azithromycin, an anti- biotic used for its treatment. Addition of new products is to sustain the market competition
Steriles Carbapenems	Meropenem	6	54	60	739.80	1,930.04	161%	Carbapenem is manufactured as per the planned campaigns. The lower contribution from Carbapenem in Q3 is due to disruption of campaigns owing to COVID-19.Developing complete range of Carbapenams to solidify the Company's position in the segment
Steriles Cephalosporin	Ceftriaxone	96	84	180	702.83	832.15	18%	
Neuromodulator	Pregabalin	30	30	60	317.03	326.72	3%	
Anti-thrombosis	Ticagrelor		6	6	6.79	32.1	373%	It is used for the prevention of stroke, heart attack and problems with blood supply in the coronary arteries.Got Commercialized in the quarter Q3 2020- 21
Urological	Nitroxoline		33	33	43.02	363.63	745%	
Gastroenterology					83.69	52.44	-37%	
Advance Intermediate					105.84	11.14	-89%	
Anti-infective/Anti Acne					6.79		7%	
Other API Product sales				0	373.48	19.77	266%	
Anti Diabetics	Canagliflozi/ Dapagliflozin		6	6				Developing Anti-diabetic portfolio
	Other Drugs	6	63	69				
Formulations					4,508.09	5,785.05	28%	It has generated growth from previous quarter. Further management is bullish stating that Penicillin products' demand was lower due to COVID-19. However, we anticipate demand to pick up from Q1 FY 2021-22.
Total		468	456	924	11,390.26	13,935.57		

EBIDTA
EBIDTA %

	2535.46	2432.33	-4%	
				Margins impacted due to export incentive not accounted for in Q4, Since the govt has not declared the rates of benefit and as a result EBIDTA and Profits are lower. Due to shutdown for expansion and upgradation of plant at Mahad, production was lower which affected the profit for the Quarter.
	22.3%	17.5%	-22%	